BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 8843221)

  • 1. Molecular subtypes and antifungal susceptibilities of serial Cryptococcus neoformans isolates in human immunodeficiency virus-associated Cryptococcosis. Cryptococcal Disease Active Surveillance Group.
    Brandt ME; Pfaller MA; Hajjeh RA; Graviss EA; Rees J; Spitzer ED; Pinner RW; Mayer LW
    J Infect Dis; 1996 Oct; 174(4):812-20. PubMed ID: 8843221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antifungal susceptibilities, varieties, and electrophoretic karyotypes of clinical isolates of Cryptococcus neoformans from Brazil, Chile, and Venezuela.
    Calvo BM; Colombo AL; Fischman O; Santiago A; Thompson L; Lazera M; Telles F; Fukushima K; Nishimura K; Tanaka R; Myiajy M; Moretti-Branchini ML
    J Clin Microbiol; 2001 Jun; 39(6):2348-50. PubMed ID: 11376089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular typing and antifungal susceptibility of clinical sequential isolates of Cryptococcus neoformans from Sao Paulo State, Brazil.
    Almeida AM; Matsumoto MT; Baeza LC; de Oliveira E Silva RB; Kleiner AA; Melhem Mde S; Mendes Giannini MJ;
    FEMS Yeast Res; 2007 Jan; 7(1):152-64. PubMed ID: 17311593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular epidemiology and antifungal susceptibility of Cryptococcus neoformans isolates from Ugandan AIDS patients.
    Pfaller M; Zhang J; Messer S; Tumberland M; Mbidde E; Jessup C; Ghannoum M
    Diagn Microbiol Infect Dis; 1998 Nov; 32(3):191-9. PubMed ID: 9884835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Electrophoretic karyotype and in vitro antifungal susceptibility of Cryptococcus neoformans isolates from AIDS patients.
    Barchiesi F; Hollis RJ; Messer SA; Scalise G; Rinaldi MG; Pfaller MA
    Diagn Microbiol Infect Dis; 1995 Nov; 23(3):99-103. PubMed ID: 8849653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro antifungal activities of amphotericin B, 5-fluorocytosine, fluconazole and itraconazole against Cryptococcus neoformans isolated from cerebrospinal fluid and blood from patients in Serbia.
    Trpković A; Pekmezović M; Barać A; Crnčević Radović L; Arsić Arsenijević V
    J Mycol Med; 2012 Sep; 22(3):243-8. PubMed ID: 23518082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates in the United States: 1992 to 1994 and 1996 to 1998.
    Brandt ME; Pfaller MA; Hajjeh RA; Hamill RJ; Pappas PG; Reingold AL; Rimland D; Warnock DW;
    Antimicrob Agents Chemother; 2001 Nov; 45(11):3065-9. PubMed ID: 11600357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antifungal susceptibilities of Cryptococcus neoformans cerebrospinal fluid isolates and clinical outcomes of cryptococcal meningitis in HIV-infected patients with/without fluconazole prophylaxis.
    Manosuthi W; Sungkanuparph S; Thongyen S; Chumpathat N; Eampokalap B; Thawornwan U; Foongladda S
    J Med Assoc Thai; 2006 Jun; 89(6):795-802. PubMed ID: 16850679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antifungal susceptibilities of Cryptococcus species complex isolates from AIDS and non-AIDS patients in Southeast China.
    Li M; Liao Y; Chen M; Pan W; Weng L
    Braz J Infect Dis; 2012; 16(2):175-9. PubMed ID: 22552461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular epidemiology of Cryptococcus neoformans isolates from AIDS patients of the Brazilian city, Rio de Janeiro.
    Igreja RP; Lazéra Mdos S; Wanke B; Galhardo MC; Kidd SE; Meyer W
    Med Mycol; 2004 Jun; 42(3):229-38. PubMed ID: 15283237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular epidemiology and in vitro antifungal susceptibility testing of 108 clinical Cryptococcus neoformans sensu lato and Cryptococcus gattii sensu lato isolates from Denmark.
    Hagen F; Hare Jensen R; Meis JF; Arendrup MC
    Mycoses; 2016 Sep; 59(9):576-84. PubMed ID: 27061834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phenotypic switching and genetic diversity of Cryptococcus neoformans.
    Sukroongreung S; Lim S; Tantimavanich S; Eampokalap B; Carter D; Nilakul C; Kulkeratiyut S; Tansuphaswadikul S
    J Clin Microbiol; 2001 Jun; 39(6):2060-4. PubMed ID: 11376035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cryptococcus neoformans and C. gattii isolates from both HIV-infected and uninfected patients: antifungal susceptibility and outcome of cryptococcal disease.
    Nascimento E; Vitali LH; Kress MRVZ; Martinez R
    Rev Inst Med Trop Sao Paulo; 2017; 59():e49. PubMed ID: 28793019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A systematic review of fluconazole resistance in clinical isolates of Cryptococcus species.
    Bongomin F; Oladele RO; Gago S; Moore CB; Richardson MD
    Mycoses; 2018 May; 61(5):290-297. PubMed ID: 29377368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro susceptibilities of clinical and environmental isolates of Cryptococcus neoformans to five antifungal drugs.
    Franzot SP; Hamdan JS
    Antimicrob Agents Chemother; 1996 Mar; 40(3):822-4. PubMed ID: 8851624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Timed-kill curves for Cryptococcus neoformans isolated from patients with AIDS.
    Rodero L; Córdoba S; Cahn P; Soria M; Lucarini M; Davel G; Kaufman S; Canteros C; Guelfand L
    Med Mycol; 2000 Jun; 38(3):201-7. PubMed ID: 10892987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current scenario of cryptococcosis and antifungal susceptibility pattern in India: a cause for reappraisal.
    Capoor MR; Mandal P; Deb M; Aggarwal P; Banerjee U
    Mycoses; 2008 May; 51(3):258-65. PubMed ID: 18399907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genotyping and antifungal susceptibility testing of Cryptococcus neoformans isolates from Cameroonian HIV-positive adult patients.
    Bertout S; Drakulovski P; Kouanfack C; Krasteva D; Ngouana T; Dunyach-Rémy C; Dongtsa J; Aghokeng A; Delaporte E; Koulla-Shiro S; Reynes J; Mallié M
    Clin Microbiol Infect; 2013 Aug; 19(8):763-9. PubMed ID: 23033854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003.
    Hsueh PR; Lau YJ; Chuang YC; Wan JH; Huang WK; Shyr JM; Yan JJ; Yu KW; Wu JJ; Ko WC; Yang YC; Liu YC; Teng LJ; Liu CY; Luh KT
    Antimicrob Agents Chemother; 2005 Feb; 49(2):512-7. PubMed ID: 15673726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serotyping of Cryptococcus neoformans strains isolated from clinical specimens in Thailand and their susceptibility to various antifungal agents.
    Poonwan N; Mikami Y; Poosuwan S; Boon-Long J; Mekha N; Kusum M; Yazawa K; Tanaka R; Nishimura K; Konyama K
    Eur J Epidemiol; 1997 Apr; 13(3):335-40. PubMed ID: 9258534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.